Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangzhou Jet Bio-Filtration Co., Ltd. (688026.SS)
Guangzhou, CN
Guangzhou Jet Bio-Filtration Co., Ltd. specializes in the research, development, manufacturing, and global distribution of a diverse range of laboratory products. Their extensive catalog features essential lab consumables like pipettes, tissue culture products, centrifuge tubes, and filtration items, alongside scientific instruments such as analyzers, various lab equipment, reagents, and gloves. The company's reach extends to approximately 50 countries worldwide, serving significant markets including the United States, Japan, Canada, Germany, Australia, and South Korea. Established in 2001, its headquarters are located in Guangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.19% | -2.17% | -2.17% | -13.53% | -13.21% | +0.74% | +8.06% | -14.71% | -70.79% | -57.41% | -57.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+1.2% Q1'26: -12.9% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-32.7% Q1'26: -125.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+10.2% Q1'26: +9.3% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+10.8% Q1'26: +6.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.0% Q1'26: +2.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.8% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.24× Q1'26: 14.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
503.93M
est: 518.10M (-2.7%)
|
855.66M
est: 854.67M (+0.1%)
|
609.82M
est: 691.00M (-11.7%)
|
463.10M
est: 586.00M (-21.0%)
|
558.66M
est: 559.00M (-0.1%)
|
565.36M
est: 652.00M (-13.3%)
|
772.00M
772.00M – 772.00M
+18.4% YoY
|
919.00M
919.00M – 919.00M
+19.0% YoY
|
| EBITDA |
169.96M
est: 147.72M (+15.1%)
|
248.79M
est: 243.69M (+2.1%)
|
174.27M
est: 197.02M (-11.5%)
|
97.95M
est: 167.09M (-41.4%)
|
167.77M
est: 145.35M (+15.4%)
|
119.68M
est: 169.53M (-29.4%)
|
200.73M
200.73M – 200.73M
+18.4% YoY
|
238.95M
238.95M – 238.95M
+19.0% YoY
|
| EBIT |
147.76M
est: 102.50M (+44.2%)
|
196.74M
est: 169.08M (+16.4%)
|
112.68M
est: 136.70M (-17.6%)
|
39.46M
est: 115.93M (-66.0%)
|
109.40M
est: 89.93M (+21.6%)
|
61.31M
est: 104.89M (-41.5%)
|
124.20M
124.20M – 124.20M
+18.4% YoY
|
147.85M
147.85M – 147.85M
+19.0% YoY
|
| Net Income |
119.37M
est: 138.83M (-14.0%)
|
171.16M
est: 170.89M (+0.2%)
|
87.71M
est: 118.00M (-25.7%)
|
34.79M
est: 73.58M (-52.7%)
|
72.19M
est: 67.50M (+7.0%)
|
48.21M
est: 96.43M (-50.0%)
|
115.71M
115.71M – 115.71M
+20.0% YoY
|
141.88M
141.88M – 141.88M
+22.6% YoY
|
| SGA |
27.71M
est: 24.45M (+13.3%)
|
36.35M
est: 40.34M (-9.9%)
|
35.66M
est: 32.61M (+9.3%)
|
19.19M
est: 27.66M (-30.6%)
|
21.56M
est: 20.24M (+6.5%)
|
—
est: 23.60M (-100.0%)
|
27.95M
27.95M – 27.95M
+18.4% YoY
|
33.27M
33.27M – 33.27M
+19.0% YoY
|
| EPS |
0.85
est: 1.00 (-15.0%)
|
1.22
est: 1.23 (-0.9%)
|
0.62
est: 0.85 (-27.1%)
|
0.25
est: 0.53 (-52.8%)
|
0.52
est: 0.49 (+6.1%)
|
0.35
est: 0.70 (-50.0%)
|
0.84
0.84 – 0.84
+20.0% YoY
|
1.03
1.03 – 1.03
+22.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Xie | Chief Financial Officer | — | male |
| Jianhua Yuan | Chairman & Chief Scientist | — | male |
| Jing He | Deputy GM & Director | — | female |
| Xiangyuan Fang | Chief Engineer | — | male |
| Ye Yuan | MD, GM & Director | — | male |
| Yong An Wu | Accounting Supervisor | — | — |
| Zhiyi Wu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688026.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
